Project Partners

A consortium of partners has been established to implement each of the Ebola vaccine projects.

 

EBOVAC1 Consortium Partners

London School of Hygiene & Tropical Medicine (UK) (coordinator) LSHTM logo
Crucell Holland, N.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) (Netherlands) Janssen logo
INSERM (France) INSERM logo
University of Oxford (UK) Oxford logo

 


EBOVAC2 Consortium Partners

 

INSERM (France) (coordinator) INSERM logo
Crucell Holland, N.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) (Netherlands) Janssen logo
Centre Muraz (Burkina Faso) Centre Muraz logo
Inserm Transfert (France) Impression
London School of Hygiene and Tropical Medicine (UK) LSHTM logo
University of Oxford (UK) Oxford logo

 

 


EBODAC Consortium Partners

London School of Hygiene and Tropical Medicine (UK) LSHTM logo
Janssen Pharmaceutical, N.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) (Belgium) Janssen logo
Grameen Foundation (USA)  Grameen logo
World Vision of Ireland (Ireland)  World Vision logo

 

 


EBOMAN Consortium Partners

Vibalogics (Germany) (coordinator) Vibalogics logo
Crucell Holland, N.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) (Netherlands) Janssen logo
Bavarian Nordic A/S (Denmark) Bavarian logo
These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
www.imi.europa.eu
Copyright © 2017 Ebovac | Terms and Conditions | WordPress development by Toast.